1374208-22-6

Basic information

• Product Name: 4-[3-(4-bromo-phenyl)-ureido]-N,N-dimethyl-benzamide
• Synonyms: 4-[3-(4-bromo-phenyl)-ureido]-N,N-dimethyl-benzamide
• CAS NO: 1374208-22-6
• Molecular Weight: 362.226
• Mol File: 1374208-22-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-[3-(4-bromo-phenyl)-ureido]-N,N-dimethyl-benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[3-(4-bromo-phenyl)-ureido]-N,N-dimethyl-benzamide(1374208-22-6)
• EPA Substance Registry System: 4-[3-(4-bromo-phenyl)-ureido]-N,N-dimethyl-benzamide(1374208-22-6)

Safety Data

• Hazardous Substances Data: 1374208-22-6(Hazardous Substances Data)

Upstream product

• 6331-71-1 4-amino-N,N-dimethylbenzamide 
• 2493-02-9 4-bromophenyl isocyanate 
• 7291-01-2 N,N-dimethyl-4-nitrobenzamide 
• 62-23-7 4-nitro-benzoic acid 

Downstream Products

• 1374208-23-7 N,N-dimethyl-4-{3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2yl)phenyl]-ureido}-benzamide 
• 1374203-76-5 4-(3-{4-[8-(6-fluoro-pyridin-3-yl)-4-morpholin-4-yl-quinazolin-2-yl]-phenyl}-ureido)-N,N-dimethyl-benzamide 
• 1374203-77-6 2-{4-[3-(4-dimethycarbamoyl-phenyl)-ureido]-phenyl}-4-morpholin-4-yl-quinazoline-7-carboxylic acid(2-dimethylamino-ethyl)-amide 
• 1374203-86-7 4-(3-(4-(7-(2-hydroxypropan-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)-N,N-dimethyl-benzamide 
• 1374203-71-0 N,N-dimethyl-4-(3-{4-[4-morpholin-4-yl-7-pyrimidin-5-yl-quinazolin-2-yl]-phenyl}-ureido)-benzamide 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE AND PYRIDO-PYRIMIDINE DERIVATIVES

The present application provides novel substituted quinazoline and pyrido- pyrimidine compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating PI3K and/or mTOR activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the PI3K/AKT/mTOR pathway. Advantageously, these compounds perform as dual PI3K/mTOR inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.